



**ASX RELEASE**  
6 March 2015

**Placement cleansing notice under section 708A(5)(e) Corporations Act - Tissue Therapies Limited (ASX Code: TIS)**

Tissue Therapies Limited ACN 101 955 088 (ASX:TIS) (**Tissue Therapies**) has today issued 2,719,749 fully paid ordinary shares at a price of \$0.21 to raise approximately \$0.57 million (**Shares**) by way of a placement to existing institutional investors (**Placement**), as outlined in Tissue Therapies' announcement on 4 March 2015.

Tissue Therapies has issued the shares without disclosure to investors under section 708A(5) *Corporations Act 2001* (Cth) (**Corporations Act**).

**Details of securities issued**

<b>Class of securities:</b>	Ordinary shares
<b>ASX Code of the securities:</b>	TIS
<b>Date of the issue of the securities:</b>	6 March 2015
<b>Total number of securities issued:</b>	2,719,749

For the purposes of section 708A(6) Corporations Act, Tissue Therapies advises that:

- 1 the Shares have been issued without disclosure to investors under Part 6D.2 Corporations Act;
- 2 this notice is given under section 708A(5)(e) Corporations Act;
- 3 as at the date of this notice, Tissue Therapies has complied with:
  - (a) the provisions of Chapter 2M Corporations Act as they apply to Tissue Therapies; and
  - (b) section 674 Corporations Act; and
- 4 as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) Corporations Act to be disclosed under section 708A(6)(e) Corporations Act.

For and on behalf of the Board of Tissue Therapies Limited.

**Drummond McKenzie**  
**Company Secretary**  
**Tissue Therapies Limited**

## **What is VitroGro<sup>®</sup> ECM**

- VitroGro<sup>®</sup> ECM is a topically applied, biomimetic scaffold, comprising a synthetic extracellular matrix (ECM) protein.
- How it works: VitroGro<sup>®</sup> ECM replaces the degraded matrix of a hard to heal wound. VitroGro<sup>®</sup> ECM binds to a prepared wound bed and provides a physical structure (a scaffold) for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as cell proliferation and migration <sup>[1]</sup>.
- An optimal scaffold: One of the characteristics of hard to heal wounds is prolonged inflammation, which damages the native ECM that would normally guide the wound healing process <sup>[1,2,3,4]</sup>. Replacement of this damaged ECM is a beneficial strategy for treating hard to heal wounds <sup>[1]</sup>. VitroGro<sup>®</sup> ECM is ideal as an ECM replacement since its structural and functional elements mimic those present in the ECM at the early stages of normal wound healing.
- Expert health economics modelling indicates that VitroGro<sup>®</sup> ECM offers the opportunity for substantially more cost effective treatment of wounds compared to the current standard of care.

[1] Widgerow AD . Deconstructing the stalled wound. Wounds 2012

[2] Schultz GS. Extracellular Matrix: review of its roles in acute and chronic wounds. World Wide Wounds. 2005

[3] Moor AN. et al. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Rep Reg. 2009

[4] International consensus, Acellular matrices for treatment of wounds. Wounds Int. 2010

## **About Tissue Therapies Limited**

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro<sup>®</sup> ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)

## **Important information**

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. This document may not be distributed or released in the United States.